نتایج جستجو برای: randomized placebo
تعداد نتایج: 282883 فیلتر نتایج به سال:
OBJECTIVE The objective of this study was to define the outcome of empiric treatment of suspected laryngopharyngeal reflux (LPR) symptoms with proton pump inhibitors (PPIs). DESIGN The authors conducted a systematic review of the English and foreign literature. Studies that used PPIs as an empiric treatment modality for suspected LPR, whether alone or in combination with other acid suppressan...
BACKGROUND Idiopathic intracranial hypertension (IIH) is a condition with few effective management options. So far, there have been no randomized controlled trials evaluating new treatments in IIH. OBJECTIVES The purpose of this paper is to outline the trial design for the Idiopathic Intracranial Hypertension Drug Trial (IIH:DT), assessing an innovative medical treatment in IIH and the ration...
In a post hoc analysis of randomized, placebo-controlled phase 2b trial in NSV, treatment with the oral JAK3/TEC family kinase inhibitor ritlecitinib stabilized active lesions and repigmented stable lesions. This compared melanocyte immune biomarkers Patients were randomized to daily or without 4-week loading dose: 200/50mg, 100/50mg, 50mg, 30mg, 10mg, placebo for 24 weeks; 50mg dose groups com...
INTRODUCTION Several observational studies suggest that statins modulate the pathophysiology of sepsis and may prevent its progression. The aim of this study was to determine if the acute administration of atorvastatin reduces sepsis progression in statin naïve patients hospitalized with sepsis. METHODS A single centre phase II randomized double-blind placebo-controlled trial. Patients with s...
PURPOSE This phase II randomized trial evaluated the efficacy and tolerability of anastrozole combined with gefitinib or anastrozole with placebo in women with hormone receptor-positive metastatic breast cancer (MBC). EXPERIMENTAL DESIGN Postmenopausal women with hormone receptor-positive measurable or evaluable MBC who had not received prior endocrine therapy for this disease stage or who de...
BACKGROUND We previously reported decreased transfusions and donor exposures in preterm infants randomized to Darbepoetin (Darbe) or erythropoietin (Epo) compared with placebo. As these erythropoiesis-stimulating agents (ESAs) have shown promise as neuroprotective agents, we hypothesized improved neurodevelopmental outcomes at 18 to 22 months among infants randomized to receive ESAs. METHODS ...
نمودار تعداد نتایج جستجو در هر سال
با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید